Dynamic lifetime risk prediction of Alzheimer’s disease with longitudinal cognitive assessment measurements

by Clinical Neuropsychologist | Wednesday, March 5, 2025 | Dementia

Abstract INTRODUCTION The progressive nature of Alzheimer’s disease (AD) highlights the importance of predicting lifetime risk and updating assessments as new data emerge. This study aimed to develop a dynamic model using longitudinal cognitive assessments for...

The tau isoform 1N4R confers vulnerability of MAPT knockout human iPSC‐derived neurons to amyloid beta and phosphorylated tau‐induced neuronal dysfunction

by Clinical Neuropsychologist | Friday, February 28, 2025 | Dementia

Abstract INTRODUCTION Human tau protein, composed of six brain-specific isoforms, is a major driver of Alzheimer’s disease (AD). The role of its isoforms however remains unclear and human AD models are scarce. METHODS We generated human MAPT– (tau–) knockout...

Performance of study partner reports in a non‐demented at‐risk sample

by Clinical Neuropsychologist | Wednesday, February 26, 2025 | Dementia

Abstract INTRODUCTION The Clinical Dementia Rating (CDR) Scale is a gold standard for staging impairment in Alzheimer’s disease and other dementias (ADRD). The Quick Dementia Rating System (QDRS) offers similar results in 3 to 5 minutes without a trained...

Plasma Alzheimer’s disease biomarker relationships with incident abnormal amyloid PET

by Clinical Neuropsychologist | Monday, February 24, 2025 | Dementia

Abstract INTRODUCTION Limited data exist on the utility of plasma biomarkers to predict incident abnormal amyloid positron emission tomography (PET). In this study we evaluate the association of plasma Alzheimer’s disease (AD) biomarkers with amyloid PET...

Physical activity may protect myelin via modulation of high‐density lipoprotein

by Clinical Neuropsychologist | Monday, February 24, 2025 | Dementia

Abstract INTRODUCTION Physical activity is associated with greater myelin content in older individuals with cerebral small vessel disease (CSVD), a condition marked by demyelination. However, potential mechanisms underlying this relationship remain understudied....

Tau‐related reduction of glucose metabolism in mild cognitive impairment occurs independently of APOE ε4 genotype and is influenced by Aβ

by Clinical Neuropsychologist | Monday, February 24, 2025 | Dementia

Abstract INTRODUCTION Positron emission tomography (PET) imaging studies have shown that amyloid beta (Aβ) is significantly correlated with glucose metabolism in mild cognitive impairment independently of the apolipoprotein E (APOE) ε4 genotype. METHODS We used a...